Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. TEZEPELUMAB (tézépélumab)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

TEZEPELUMAB (tézépélumab)

Medicine - Posted on Apr 21 2022
Active substance (DCI)
  • tézépélumab
history (1)
  • 4/14/22

    TEZEPELUMAB (tézépélumab)

    Autorisation d’accès précoce refusée à la spécialité TEZEPELUMAB dans l’indication « Traitement de fond additionnel de l’ast...
    icône flèche
Technical information
ATC code
  • R03DX11
Manufacturer
ASTRAZENECA
Presentation

TEZEPELUMAB 210 mg, solution injectable en seringue préremplie
Boite de 1 seringue préremplie

All our publications
    Drug therapy Immune system diseases - miscellaneous Kidney diseases Transfusions, transplantations

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
60qCxVwLYzvgDD4G